Clinical Validation of a Novel Software Tool to Guide the Intravenous-to-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases

被引：0
|
作者：
Hoffert, Yannick [1 ]
Wang, Zhigang [1 ]
Fumery, Mathurin [2 ,3 ]
Nachury, Maria [4 ]
Bazoge, Maeva [5 ]
Buisson, Anthony [5 ]
Dreesen, Erwin [1 ]
机构：
[1] Katholieke Univ Leuven, Leuven, Vlaams Brabant, Belgium
[2] Picardie Jules Verne Univ, CHU Amiens, Amiens, Picardie, France
[3] Picardie Jules Verne Univ, Peritox, Amiens, Picardie, France
[4] Lille Univ & Hosp, Lille, Nord Pas De Cal, France
[5] Univ Clermont Auvergne, CHU Clemront Ferrand, Clermont Ferrand, Auvergne, France
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001034524.01104.8d
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1289
引用
收藏
页码：S921 / S922
页数：2
相关论文
共 50 条
  • [1] Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study
    Buisson, Anthony
    Nachury, Maria
    Reymond, Maud
    Yzet, Clara
    Wils, Pauline
    Payen, Laure
    Laugie, Marie
    Manlay, Luc
    Mathieu, Nicolas
    Pereira, Bruno
    Fumery, Mathurin
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (09) : 2338 - 2346
  • [2] The persistence of subcutaneous infliximab is equivalent to intravenous form in patients with inflammatory bowel diseases
    Bothorel, L.
    Laharie, D.
    Poullenot, F.
    Gohier, E.
    Chevrier, C.
    Berger, A.
    Zerbib, F.
    Riviere, P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1490 - I1490
  • [3] Maintenance of clinical, biochemical and transmural remission in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab
    Sed, N. Piazza O.
    Maregatti, M. C.
    Pessarelli, T.
    Vigano, C.
    Conforti, F.
    Noviello, D.
    Bezzio, C.
    Amoroso, C.
    Molteni, C.
    Anolli, M. P.
    Pirola, L.
    Saibeni, S.
    Fraquelli, M.
    Vecchi, M.
    Caprioli, F.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1669 - I1669
  • [4] Effectiveness of Switching to Subcutaneous Infliximab in Pediatric Inflammatory Bowel Disease Patients on Intravenous Maintenance Therapy
    Gianolio, Laura
    Armstrong, Katherine
    Swann, Ewan
    Shepherd, Rhona
    Henderson, Paul
    Wilson, David C. C.
    Russell, Richard K. K.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 77 (02): : 235 - 239
  • [5] Switching from intravenous to subcutaneous Infliximab in patients with immune mediated diseases in clinical remission
    Viazis, N.
    Karamanakos, A.
    Mousourakis, K.
    Christidou, A.
    Fousekis, F.
    Mpakogiannis, K.
    Koukoudis, A.
    Katsanos, K.
    Christodoulou, D.
    Cheila, M.
    Tzouvala, M.
    Zacharopoulou, E.
    Palatianou, M.
    Giouleme, O.
    Katsoula, A.
    Liatsos, C.
    Kyriakos, N.
    Zampeli, E.
    Papathanasiou, E.
    Theodoropoulou, A.
    Karmiris, K.
    Psaroudakis, I
    Tribonias, G.
    Gazi, S.
    Mole, E.
    Dimitroulas, T.
    Koutsianas, C.
    Vasilopoulos, D.
    Fragoulis, G.
    Michalakeas, N.
    Papagoras, C.
    Panagakis, P.
    Papoutsaki, M.
    Chasapi, V
    Stratigos, A.
    Katsikas, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1773 - i1773
  • [6] An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study
    D'Amico, Ferdinando
    Massimino, Luca
    Palmieri, Giulia
    Buono, Arianna Dal
    Gabbiadini, Roberto
    Caron, Benedicte
    Moreira, Paula
    Silva, Isabel
    Bosca-Watts, Maia
    Innocenti, Tommaso
    Dragoni, Gabriele
    Bezzio, Cristina
    Zilli, Alessandra
    Furfaro, Federica
    Saibeni, Simone
    Chaparro, Maria
    Garcia, Maria Jose
    Michalopoulos, George
    Viazis, Nikos
    Mantzaris, Gerassimos J.
    Ellul, Pierre
    Gisbert, Javier P.
    Magro, Fernando
    Peyrin-Biroulet, Laurent
    Armuzzi, Alessandro
    Ungaro, Federica
    Danese, Silvio
    Fiorino, Gionata
    Allocca, Mariangela
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54 (11)
  • [7] Environmental impact and costs of a switching program of intravenous to subcutaneous infliximab in Inflammatory Bowel Disease
    Oliveira, R.
    Roseira, J.
    Araujo, N.
    Cavaco, C.
    Andre, J.
    Sousa, M.
    Tavares de Sousa, H.
    Cunha, M.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1681 - i1681
  • [8] Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
    Lee, Bokyeong
    Kim, Minjee
    Kim, Eun Ran
    Hong, Sung Noh
    Chang, Dong Kyung
    Kim, Young-Ho
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [9] Effectiveness of Switching to Subcutaneous Infliximab in Inflammatory Bowel Disease Patients with Inadequate Biochemical Response during Intravenous Administration
    Kim, M.
    Lee, B.
    Kim, E. R.
    Hong, S. N.
    Chang, D. K.
    Kim, Y. H.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1443 - i1444
  • [10] Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
    Remy, Clotilde
    Caron, Benedicte
    Gouynou, Celia
    Haghnejad, Vincent
    Jeanbert, Elodie
    Netter, Patrick
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (24)
12345